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Hepatology CommuniCations, Vol. 2, no. 11, 2018  
FXR and TGR5 Agonists Ameliorate 
Liver Injury, Steatosis, and Inflammation 
After Binge or Prolonged Alcohol Feeding 
in Mice
Arvin Iracheta-Vellve,1 Charles D. Calenda,1* Jan Petrasek,1* Aditya Ambade,1 Karen Kodys,1 Luciano Adorini,2 and Gyongyi Szabo1
Bile acids (BAs) activate various dedicated receptors, including the farnesoid X receptor (FXR) and the Takeda G protein-
coupled receptor 5 (TGR5). The FXR agonist obeticholic acid (OCA) is licensed for the treatment of primary biliary chol-
angitis and has shown promising results in NASH patients, whereas TGR5 agonists target inf lammation and metabolism. 
We hypothesized that FXR and/or TGR5 agonists may be therapeutic in early alcoholic liver disease (ALD) in mice, in 
which hepatic inf lammation plays a major role. OCA, INT-777, and INT-767 are BA derivatives with selective agonist 
properties for FXR, TGR5, or both, respectively. These compounds were tested in two mouse models (3-day binge model 
and prolonged Lieber DeCarli diet for 12 days) of early ALD. Serum alanine aminotransferase and liver histology were used 
to assess liver injury, Oil Red O staining of liver sections to assess steatosis, and real-time polymerase chain reaction to assess 
changes in gene expression. In the ethanol binge model, treatment with OCA and INT-777 decreased hepatic macrovesicu-
lar steatosis and protected from ethanol-induced liver injury. After prolonged ethanol administration, mice treated with 
OCA, INT-767, or INT-777 showed decreased hepatic steatosis, associated with reduced liver fatty acid synthase protein 
expression, and protection from liver injury. Treatment with BA receptor agonists in both models of ethanol administration 
modulated lipogenic gene expression, and decreased liver interleukin-1β mRNA expression associated with increased ubiq-
uitination of NLRP3 inf lammasome through cyclic adenosine monophosphate–induced activation of protein kinase A. 
Conclusion: OCA, INT-767, or INT-777 administration is effective in reducing acute and chronic ethanol-induced steatosis 
and inf lammation in mice, with varying degrees of efficacy depending on the duration of ethanol administration, indicating 
that both FXR and TGR5 activation can protect from liver injury in ALD models. (Hepatology Communications 
2018;2:1379-1391)
Excessive alcohol consumption leads to alco-holic liver disease (ALD), which is a cause of considerable morbidity and mortality in the 
Western world. ALD consists of a spectrum of stages, 
ranging from simple steatosis to alcoholic steato-
hepatitis (ASH) to fibrosis, cirrhosis, and ultimately 
hepatocellular carcinoma.(1) In its initial phase, it is 
characterized by hepatic lipid accumulation and innate 
Abbreviations: ALD, alcoholic liver disease; ALT, alanine aminotransferase; ASH, alcoholic steatohepatitis; BA, bile acids; cAMP, cyclic 
adenosine monophosphate; Casp-1, caspase-1; EtOH, ethanol; FASN, fatty acid synthase; FXR, farnesoid X receptor; H&E, hematoxylin and 
eosin; IL, interleukin; NLRP3, NACHT domain-, leucine-rich repeat-, and PYD-containing protein 3; OCA, obeticholic acid; PF, pair-fed; 
PKA, protein kinase A; SREBP, sterol regulatory element–binding protein; TGR5, Takeda G protein-coupled receptor 5; and WT, wild type.
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immune system activation leading to chronic inflam-
mation.(2) Activation of resident liver macrophages, 
the Kupffer cells (KCs), plays a critical role in the ini-
tiation and development of ALD, and the NLRP3 
inflammasome has been found to be activated in 
KCs of ethanol-fed mice.(3) Elevated liver expression 
of inflammasome components (interleukin [IL]-1β, 
IL-18, caspase-1 [Casp-1]), correlated with liver injury, 
has also been found in patients with ALD, confirming 
the important role of innate immune system activation 
in the pathogenesis of ALD. However, despite signif-
icant advances in understanding ALD pathogenesis, 
very few treatment options are still available.(4)
Bile acids (BAs) act as signaling molecules, acti-
vating two dedicated receptors: farnesoid X receptor 
(FXR), a member of the nuclear receptor superfamily 
of transcription factors, and transmembrane G pro-
tein-coupled receptor 5 (TGR5).(5) FXR (NR1H4), 
highly expressed in liver, gut, kidney and adrenal 
glands, regulates BA synthesis, lipid, glucose and 
energy homeostasis, as well as inflammation and 
fibrosis, all of which are important components in 
the pathogenesis of NASH and ASH.(6-9) TGR5 (also 
known as G-protein coupled bile acid receptor 1) is 
more broadly expressed than FXR and induces gall-
bladder filling, exerts potent anti-inflammatory effects, 
enhances energy expenditure, prevents obesity, and 
decreases insulin resistance.(9) Therefore, the two BA 
receptors play complementary roles in the regulation of 
several metabolic and inflammatory pathways. Recent 
reports have highlighted the potential of synthetic ago-
nists for these receptors in various liver disease models 
and in the treatment of different chronic liver dis-
eases.(10,11) The FXR agonist obeticholic acid (OCA, 
also known as INT-747) has been recently approved for 
the treatment of primary biliary  cholangitis, a chronic 
autoimmune liver disease.(8) This drug has also shown 
promising results in the treatment of NASH in a phase 
II trial,(12) demonstrating anti-inflammatory and anti-
fibrotic effects in the liver, and is currently in a phase 
III clinical trial in NASH patients (ClinicalTrials.
gov identifier, NCT02548351; sponsored by Intercept 
Pharmaceuticals).
Although ASH and NASH have distinct triggers, 
chronic alcohol consumption and obesity-associated 
lipotoxicity, respectively, both liver diseases share over-
lapping pathogenic mechanisms, including steato-
sis and altered hepatocyte lipid metabolism, hepatic 
stellate cell activation, innate immune system activa-
tion with subsequent inflammation, fibrosis, and liver 
injury.(13) However, molecular mechanisms can differ, 
as indicated by the predominant involvement of inflam-
masome activation and IL-1β signaling in ASH.(14)
Here, we have tested the hypothesis that FXR and/
or TGR5 agonists may be therapeutic in the treat-
ment of early ASH in mice. The results indicate that 
both FXR and TGR5 activation can protect from liver 
injury in ALD models.
Materials and Methods
animal stuDies
Six- to 8-week-old female C57BL/6 wild-type 
(WT) mice ( Jackson Laboratory, Bar Harbor, ME) were 
used. OCA,(15) INT-777,(15) and INT-767(16) are 
BA derivatives with selective agonist properties for FXR, 
TGR5, or both, respectively (Supporting Information 
Fig. S1A). These bile acid receptor agonists were gen-
erously provided by Intercept Pharmaceuticals. These 
compounds were tested in two mouse models of early 
alcohol steatohepatitis. In the binge model, an etha-
nol gavage (20% vol/vol ethanol) was administered for 
3 days to mice concurrently treated with either ago-
nist (30 mg/kg/day) or vehicle (0.5% methylcellulose) 
through oral gavage (Supporting Information Fig. 
S1B). In the prolonged ethanol model, mice were given 
a Lieber DeCarli diet for 12 days (7 days of 5% vol/vol 
ethanol after a 5-day ramp-up), with oral administra-
tion of vehicle or agonist at 30 mg/kg every day during 
artiCle inFormation:
From the 1University of Massachusetts Medical School, Worcester, MA; 2Intercept Pharmaceuticals Inc, New York, NY.
aDDress CorresponDenCe anD reprint reQuests to: 
Gyongyi Szabo, M.D, Ph.D.
Department of Medicine
University of Massachusetts Medical School





Hepatology CommuniCations, Vol. 2, no. 11, 2018 iraCHeta-VellVe et al.
1381
ramp-up period and for 4 days spread throughout the 
remaining 7 days as we previously described (Supporting 
Information Fig. S1C).(17) All animals received proper 
care in agreement with animal protocols approved by 
the Institutional Animal Use and Care Committee of 
the University of Massachusetts Medical School.
BioCHemiCal assays
Serum alanine aminotransferase (ALT) was deter-
mined using a kinetic method (D-Tek LLC., Bensalem, 
PA).
rna analysis
RNA was purified using the RNeasy kit 
(Qiagen Sciences) and on-column DNA digestion. 
Complementary DNA was transcribed with the Reverse 
Transcription System (Promega Corp.). Quantitative 
PCR (qPCR) was performed using Sybr-Green and 
iCycler from BioRad (Bio-Rad Laboratories Inc.).
HistopatHologiCal analysis
Liver sections were stained with hematoxylin and 
eosin (H&E) or Oil Red O and analyzed by micros-
copy, and positive staining was quantified using ImageJ 
(NIH) as previously described.(17)
protein analysis
Whole-cell lysates were extracted from liver, and 
20 µg of liver extracts were separated on polyacryl-
amide gel and transferred to a nitrocellulose mem-
brane. Target proteins were detected by western blot 
and immunostaining with specific primary antibody, 
followed by horseradish peroxidase–labeled second-
ary antibody. The specific immunoreactive bands 
of interest were detected by chemiluminescence 
(Bio-Rad). Digital system (ImageQuant LAS 4000; 
GE Healthcare) was used for image acquisition. 
Antibodies were specific for Fatty Acid Synthase 
(3180S, Cell Signaling Technology), Phospho-
(Ser/Thr) PKA Substrate (9621S, Cell Signaling 
Technology), CYP7A1 (MABD42, EMD Millipore), 
and Casp1p10 (sc-514, Santa Cruz Technology).
statistiCal analysis
Two-sided t tests or analysis of variance and 
Dunnett’s multiple comparison posttest were used to 
compare the means of groups as appropriate. Data are 
shown as mean ± SEM and were considered statisti-
cally significant at P < 0.05 (*P < 0.05 versus baseline; 
**P ≤ 0.001 versus baseline; #P ≤ 0.05 versus vehi-
cle-treated ethanol [EtOH] condition). We used SPSS 
19.0 (IBM SPSS, Chicago, IL) and GraphPad Prism 
7.0c (San Diego, CA) for calculations.
Results
inCreaseD Cyp7a1 eXpression 
in alD
Ethanol exposure is associated with increased bile 
acid signaling,(18) with increasing evidence to suggest 
that an altered bile acid homeostasis may be responsible 
for some pathogenic changes observed in ALD.(19,20) It 
has been previously reported that CYP7A1 mRNA is 
expressed by primary human hepatocytes after stimu-
lation with ethanol.(21) For this reason, we explored 
signs of altered bile acid signal transduction in human 
livers from patients with acute alcoholic hepatitis. 
Remarkably, we found increased CYP7A1 protein 
expression in the three human livers with alcoholic 
hepatitis tested, compared with three healthy controls 
(Fig. 1A). It should be noted that CYP7A1 expres-
sion was hepatocyte-specific, with connective tissue 
in these fibrotic livers negative for CYP7A1 stain-
ing. We wondered whether these findings would also 
extrapolate to a shortened 12-day ALD murine Lieber 
DeCarli model of prolonged ethanol administration. 
These mouse livers showed increased CYP7A1 pro-
tein expression compared with their pair-fed (PF) con-
trols (Fig. 1B). These data indicate that in humans and 
mice prolonged ethanol exposure results in increased 
CYP7A1 expression, suggesting altered bile acid 
signaling.
We hypothesized that reducing CYP7A1 expres-
sion may be therapeutic, and thus BA receptor ago-
nists may represent a suitable treatment in mice with 
ALD. We first tested whether delivery of BA recep-
tor agonists in a short-term and long-term alcohol 
feeding model would be sufficient to target CYP7A1 
protein expression, independent of ethanol admin-
istration. Thus, we administered three different BA 
receptor agonists over a 3-day regimen (short term) 
and a 12-day regimen (prolonged term) of daily alco-
hol oral gavage. We used OCA, INT-767, and INT-
777, which differentially target BA receptors. OCA 
is an FXR agonist, INT-777 is a TGR5 agonist, and 
INT-767 is a dual FXR/TGR5 agonist (Supporting 
iraCHeta-VellVe et al. Hepatology CommuniCations, november 2018
1382
Information Fig. S1A). We found that in both short-
term and prolonged models, daily administration 
of OCA and INT-767, both of which target FXR, 
significantly reduced CYP7A1 protein expression in 
mouse livers (Fig. 2A). Conversely, CYP7A1 expres-
sion was not affected by the TGR5 agonist INT-777, 
as expected. We then administered WT mice with a 
12-day ethanol feeding and found that, similarly, etha-
nol-treated mice expressed reduced levels of CYP7A1 
protein in the liver when simultaneously treated with 
FXR agonists OCA or INT-767, compared with their 
PF controls, but not with the TGR5 agonist INT-777 
(Fig. 2C). Interestingly, INT-767 showed the greatest 
reduction of liver CYP7A1 expression, possibly due 
to the three-fold higher potency in FXR activation of 
INT-767 compared with OCA or to the reinforcing 
effect of the crosstalk between TGR5 and FXR.(22)
Ba reCeptor agonists 
attenuate liVer inJury anD 
miCroVesiCular steatosis 
aFter aCute etHanol 
aDministration
In the binge ethanol injury model, treatment with 
OCA and INT-777 decreased hepatic microvesicu-
lar steatosis detected by H&E histology, whereas the 
FXR/TGR5 dual agonist, INT-767, resulted only 
in mild improvement of these histological features 
(Fig. 3A). We then analyzed liver lipid accumulation 
through Oil Red O staining and found reduced levels 
in the percent of positive Oil Red O area (Fig. 3B,C) 
with each BA receptor agonist treatment, albeit only 
OCA showed a statistically significant reduction com-
pared with vehicle treatment. In the acute binge etha-
nol model, mice treated with OCA showed significant 
Fig. 1. Increased CYP7A1 expression in human and mouse ALD. (A) Three human livers from patients with severe alcoholic 
hepatitis and three healthy controls were probed for CYP7A1 protein expression through immunohistochemistry. Images are shown 
at 100-times magnification, with inset shown at 200-times magnification. Numbers indicate patient identification number. WT mice 
were given a Lieber DeCarli ethanol diet for 12 days. (B) Mice were sacrificed and livers analyzed for CYP7A1 protein expression 
through western blot. Densitometry of ethanol-fed group compared with the PF, calorie-matched control group was assessed using 
ImageJ software (n = 5 for PF group, n = 8 for ethanol-fed group).
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protection from liver injury, as measured by serum 
ALT, compared with ethanol-binged mice treated 
with vehicle (Fig. 3D). Treatment with OCA resulted 
in slight attenuation in liver-to-body-weight ratio 
induced by acute ethanol administration (Supporting 
Information Fig. S2A), whereas BA receptor ago-
nist treatment had no effect on serum ethanol levels 
(Supporting Information Fig. S2B).
Ba reCeptor agonists 
attenuate liVer inJury anD 
maCroVesiCular steatosis in 
early alD
We similarly analyzed mouse liver sections through 
H&E histology and Oil Red O staining after prolonged 
ethanol administration, resulting in liver injury and 
Fig. 2. (A) FXR agonists reduce CYP7A1 protein expression. In the short-term, 3-day model, WT mice were treated with either 
agonist (30 mg/kg/day) or vehicle (0.5% methylcellulose) for 3 days through oral administration. (B) In the prolonged, 12-day model, 
mice were given a Lieber DeCarli diet for 12 days, with oral administration of vehicle (0.5% methylcellulose) or BA receptor agonist at 
30 mg/kg every day during ramp-up period and for 4 days spread throughout the remaining 7 days (Supporting Information Fig. S1). 
(A,B) CYP7A1 protein expression was assessed in whole-cell liver lysates. (C) In the prolonged model, changes in CYP7A1 protein 
expression were assessed in whole-cell liver lysates from ethanol-treated mice dosed with either agonist or vehicle, compared with its 
PF controls.
iraCHeta-VellVe et al. Hepatology CommuniCations, november 2018
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steatosis compared with PF mice (Fig. 4A,B) (Table 2). 
Mice treated with vehicle plus ethanol showed sub-
stantial accumulation of macrovesicular steatosis (Fig. 
4A), a phenotype not present in the acute liver injury 
model (Fig. 3A). Furthermore, H&E staining showed 
that mice treated with OCA, INT-767, or INT-777 
had decreased hepatic macrovesicular steatosis in the 
liver compared with the vehicle-treated ethanol group 
(Table 1). Likewise, Oil Red O staining showed a sig-
nificant decrease in steatosis after treatment with each 
of the three BA receptor agonists (Fig. 4B,C).
To test whether changes in serum ALT correlated 
with changes in liver structure, we performed liver his-
tology. Prolonged ethanol administration resulted in 
liver injury, as indicated by elevated serum ALT (Fig. 
4D). Interestingly, OCA treatment did not attenuate 
liver damage after 12 days of chronic ethanol admin-
istration. In this prolonged alcohol feeding model 
that causes features of early ALD, only treatment 
with the FXR/TGR5 dual agonist INT-767 reduced 
serum ALT levels significantly compared with the 
vehicle-treated ethanol group (Fig. 4D). BA receptor 
Fig. 3. Bile acid receptor agonists attenuate liver injury and microvesicular steatosis after acute ethanol injury. WT mice treated with 
bile acid receptor agonist or vehicle were exposed to ethanol or sugar binges. Liver injury and microvesicular steatosis was assessed 
by H&E histology on liver sections (A-C), and serum ALT was evaluated (D). Steatosis was assessed by Oil Red O staining (B), and 
percent-positive staining was quantified by ImageJ software from the average of five random images per sample (C). *P < 0.05 compared 
with baseline; #P < 0.05 compared with vehicle-treated ethanol group (n = 5 for PF, 10 for ethanol, per treatment).
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agonist treatment did not result in changes in serum 
ethanol levels or body-to-weight ratios (Supporting 
Information Fig. S1C,D).
Bile aCiD reCeptor agonists 
DeCrease steatosis tHrougH 
Fatty aCiD syntHase 
DoWnregulation
The role of FXR in lipid and glucose metabolism 
has been explored extensively explored.(23-26) FXR 
activation lowers plasma and liver triglyceride lev-
els by enhancing plasma triglyceride clearance(27) and 
repressing sterol regulatory element–binding pro-
tein (SREBP) 1c-mediated hepatic lipogenesis.(28) 
Therefore, it is likely that BA receptor agonists directly 
modulate fatty acid synthesis (FASN) pathways. 
Based on the fact that ethanol administration led to 
an increase in steatosis, but more importantly, having 
shown that each of these compounds lead to a decrease 
in steatosis, we analyzed protein expression changes of 
FASN.
Fig. 4. Bile acid receptor agonists attenuate liver injury and macrovesicular steatosis in early ALD. WT mice treated with bile acid agonist 
or vehicle were exposed to 12 days of prolonged ethanol or PF liquid diet. Liver injury and microvesicular steatosis was assessed by H&E 
histology on liver sections (A-C), and serum ALT was evaluated (D). Steatosis was assessed by Oil Red O staining (B), and percent-positive 
staining was quantified by ImageJ software from the average of five random images per sample (C). *P < 0.05 compared with baseline; 
**P < 0.001 compared with baseline; #P < 0.05 compared with vehicle-treated ethanol group (n = 5 for PF, 10 for ethanol, per treatment).
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We found no change in expression of FASN in 
mouse livers after short acute binge ethanol or after 
prolonged ethanol administration when treated with 
vehicle (Fig. 5A). Although it has been previously 
shown that ethanol induces an increase in FASN 
through SREBP-1, an effect likely mediated through 
acetaldehyde,(29) the absence of change from PF to 
ethanol-treated groups might be due to the fact that 
the PF controls receive either calorie-matched sugar 
binge or iso-caloric Lieber DeCarli diet for the short 
term and prolonged term models, respectively, both of 
which may increase FASN protein expression com-
pared with chow-fed mice. We found a statistically sig-
nificant reduction in FASN protein expression in the 
acute binge model after treatment with OCA. More 
importantly, in the prolonged model, in which steatosis 
is greater than in the short-term model, treatment with 
all tested BA receptor agonists effectively reduced eth-
anol-induced FASN protein expression (Fig. 5B-D). 
The lipogenic and lipolytic changes correlate with pre-
viously described reversal in pathology associated with 
the development of ALD.(30,31)




To assess the effect of BA receptor agonists on eth-
anol-induced inflammation, we analyzed changes in 
pro-inflammatory signaling, First, we found that BA 
receptor agonist treatment consistently reduced expres-
sion of IL-1β (Supporting Information Fig. S3A,B), 
a known driver of ethanol-induced inflammation in 
the liver. Based on these results, we hypothesized that 
BA receptor agonists were inhibiting inflammasome 
signaling.
To test this possibility, we first probed for Casp-1 
cleavage in the liver, indicative of inflammasome activ-
ity. We found increased Casp-1 cleavage (Casp-1p10) 
in both vehicle-treated acute and prolonged ethanol 
models (Fig. 6A,B). This increase was slightly reduced 
following treatment with OCA and INT-767, but not 
INT-777 (Fig. 6A,B). To gain a better understanding 
of the mechanism by which these BA receptor agonists 
could modulate inflammasome signaling, we tested 
whether inflammasome inhibition involved cyclic ade-
nosine monophosphate–induced activation of protein 
kinase A (PKA), resulting in ubiquitination and poten-
tial subsequent degradation of NLRP3.(32)
Our lab has previously shown that the NLRP3 sen-
sor is a key driver of inflammation in ALD through 
activation from uric acid and adenosine triphos-
phate (ATP), released by damaged hepatocytes.(17,33) 
In ALD models, we found that both FXR and TGR5 
agonists increase phosphorylated PKA substrate, sug-
gesting PKA activity, especially after treatment with 
TGR5 agonists (Fig. 6C). To test whether PKA activ-
ity resulted in increased ubiquitination of NLRP3, we 
performed immunoprecipitation of NLRP3 and probed 
for ubiquitin, observing an increase in ubiquitin-tagged 
NLPR3, especially following INT-767 treatment (Fig. 
6D). Consistent with increased NLRP3 ubiquitina-
tion, both FXR and TGR5 agonists inhibited expres-
sion of IL-1β transcripts in the prolonged ALD model 
(Table 2) (Supporting Information Fig. S3B), whereas 
they were significantly inhibited only by OCA in the 
acute ALD model (Table 1) (Supporting Information 
Fig. S3A). These data are further supported by the 
previously reported role of TGR5-cyclic adenosine 
taBle 1. summary oF attenuation in serum 
alt, steatosis, anD inDuCtion oF liVer 
il-1β mrna aFter treatment WitH Ba 
reCeptor agonists in miCe aDministereD 
WitH Binge etHanol
Note: Percentages indicate the amount of increase compared with 
its own baseline, in which vehicle-treated (“No Treatment”) is 
shown as the highest increase (100%).
taBle 2. summary oF attenuation in serum 
atl, steatosis, anD inDuCtion oF liVer 
il-1β mrna aFter treatment WitH Ba 
reCeptor agonists aFter prolongeD 
etHanol
Note: Percentages indicate the amount of increase compared with 
its own baseline, where vehicle-treated (No Treatment) is shown 
as highest increase (100%).
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Fig. 5. Bile acid receptor agonists decrease steatosis through FASN downregulation. WT mice treated with bile acid agonist or vehicle 
were exposed to ethanol or sugar binges, or to 12 days of prolonged ethanol or PF liquid diet. FASN expression was assessed by probing 
for FASN in liver lysate by western blot in the acute (A) and prolonged ethanol feeding model (B). Individual western blots are shown 
in (C), where acute is shown first followed by prolonged ethanol administration, listed in groups according to treatment. Quantification 
was done using ImageJ software. *P < 0.05 compared with baseline; **P < 0.001 compared with vehicle-treated group (n = 4-5 for PF, 
9-10 for ethanol, per treatment).
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Fig. 6. BA agonists regulate NLRP3 inflammasome through PKA. WT mice treated with BA agonist or vehicle were exposed 
to ethanol or sugar binges, or to 12 days of prolonged ethanol or PF liquid diet. Effects on inf lammasome activity were assessed by 
probing for Casp-1 cleavage in liver lysate by western blot in the acute (A) and prolonged ethanol feeding model (B). PKA activity in 
the prolonged ethanol model was assessed by probing for phospho-PKA substrate in liver lysate (C). Ubiquitination of NLRP3 was 
assessed by immunoprecipitation of NLRP3, followed by probing of ubiquitin protein by western blot (D).
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monophosphate (cAMP) signaling in Kupffer cells 
in being able to reduce lipopolysaccharide-induced 
expression of pro- inflammatory cytokines such as 
IL-1β and tumor necrosis factor α.(34) Taken together, our 
results indicate that BA receptor agonists lower ste-
atosis and inflammation, and improve liver pathology 
in ALD models by targeting NLRP3 inflammasome 
signaling as well as reducing FASN-induced steatosis.
Discussion
Despite significant advances in understanding the 
pathogenesis of ALD, very few treatment options are 
currently available.(4,35) Here, we have tested the thera-
peutic potential of BA receptor agonists in two mouse 
models of alcoholic liver injury. Our data show that 
FXR and TGR5 agonists inhibit liver CYP7A1 expres-
sion, which is increased in ALD, reduce liver damage, 
and blunt hepatic steatosis through FASN downreg-
ulation. FXR agonists inhibit NLRP3 inflammasome 
signaling, as detected by reduced Casp-1 cleavage. In 
the two ALD models tested, FXR and TGR5 agonists 
increase phosphorylated PKA, resulting in increased 
ubiquitination of NLRP3 inflammasome, and leading 
to decreased expression of IL-1β transcripts.
FXR and TGR5 play key roles in ALD by modu-
lating BA metabolism, lipid and glucose metabolism, 
as and well as inflammation and liver regeneration.(36) 
Alcohol consumption induces hepatic lipid accumu-
lation and immune cell infiltration, and increases oxi-
dative stress.(4,35) More importantly, chronic alcohol 
consumption results in increased BA pool and decreased 
excretion of BA, suggesting that alcohol consumption 
may affect the enterohepatic circulation.(37) However, 
acute alcohol exposure has been reported to induce BA 
synthesis in humans and primary hepatocytes.(21,38) 
Hence, we chose to test both acute and prolonged 
alcohol exposure models (Supporting Information Fig. 
S1). Treatment with OCA, INT-767, or INT-777 was 
effective in reducing ethanol-induced steatosis after 
acute or chronic ethanol administration. However, only 
mice treated with the selective FXR agonist, OCA, 
showed protection from acute binge ethanol-induced 
liver injury, whereas mice treated with the dual FXR-
TGR5 agonist, INT-767, showed liver protection after 
chronic ethanol exposure. Our findings demonstrate 
that treatment with FXR and/or TGR5 agonists results 
in improved biochemical and histological features of 
early ALD, with varying degrees of efficacy depending 
on the mode of ethanol administration.
Ethanol-induced CYP7A1 signaling in hepato-
cytes may represent a therapeutic target through 
which steatosis and inflammation can be attenuated. 
Consistent with a previous report,(21) we show here 
that ethanol exposure increases CYP7A1 production 
in the liver, which catalyzes the rate-limiting step in 
BA biosynthesis from cholesterol. BA receptor ago-
nists downregulate expression of CYP7A1, and the 
resulting negative feedback loop, decreasing bile acid 
synthesis, may indirectly result in decreased steatosis. 
FXR agonist treatment induces expression of small 
heterodimer partner 1, an atypical member of the 
nuclear receptor family,(39) which represses expression 
of CYP7A1 by inhibiting the activity of liver recep-
tor homolog 1, an orphan nuclear receptor known 
to positively regulate CYP7A1 expression.(40) In our 
ALD models, treatment with OCA and INT-767, 
both of which signal through FXR (but not INT-
777), decreases CYP7A1 expression, confirming that 
administration of these FXR agonists induces the 
expected effect in the liver of mice undergoing alco-
hol-induced liver injury.
Our study, based on two murine models of ethanol 
administration, is supported by a report showing that 
OCA treatment results in decreased hepatic steatosis 
and oxidative stress in a model of liver injury induced 
by ethanol combined with a low-protein diet.(41) 
This study suggests that reduced lipid accumulation 
is mediated by FXR-induced regulation of FASN 
and SREBP1c expression.(42) In addition, FXR acti-
vation by the specific agonist WAY-362450 has been 
shown to protect mice from ALD development.(43) 
Confirming and extending these results, our data show 
that in both models of ethanol-induced liver injury, and 
in particular in the prolonged model in which steato-
sis is greater, treatment with all BA receptor agonists 
tested reduces ethanol-induced FASN protein expres-
sion, providing an explanation for the beneficial effects 
of FXR and TGR5 activation on ALD-induced liver 
pathology.(30,31)
Pathogen-associated molecular patterns from 
bacterial fragments drive TLR4-mediated inflam-
mation.(44) Specifically relevant to ALD is the NLRP3-
inflammasome, a multiprotein complex primed through 
TLR4 signaling and activated by release of endogenous 
damage-associated molecular patterns, such as hepato-
cyte-derived ATP and uric acid.(17,33) We have previ-
ously shown that not only is inflammation a driver of 
ALD, but its effects are long lasting, even after ethanol 
exposure has stopped, by decreasing the liver’s intrinsic 
ability to regenerate and recover.(45)
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Our results show that both FXR and TGR5 activa-
tion contribute to ameliorate liver pathology in ALD 
models. Although TGR5 is expressed in many tissues, 
including intestine, endocrine glands, adipocytes, mus-
cle, gallbladder, brain and enteric nervous system, its 
hepatic expression is limited to Kupffer cells, macro-
phages, sinusoidal endothelial cells, cholangiocytes, 
gallbladder epithelial cells, and gallbladder smooth 
muscle cells, but is absent in hepatocytes.(34,46) TGR5 
activation in macrophages by INT-777 potently inhib-
its inflammation by targeting cAMP- and nuclear 
factor (NF) kB signaling,(47) and bile acids inhibit 
LPS-induced proinflammatory cytokine expression 
in macrophages(46) and in Kupffer cells(34) through 
TGR5-cAMP-dependent pathways.(34) Therefore, 
TGR5 agonists may inhibit inflammation and steato-
sis in ALD also by targeting Kupffer cells–mediated 
inflammasome activation. Moreover, FXR activa-
tion inhibits NF-kB signaling in the liver(48) and in 
the intestine,(49) leading to marked inhibition of 
inflammatory responses.(50) When we assessed the 
effect of FXR/TGR5 agonists in protecting against 
alcohol-induced inflammation, we found that IL-1β 
mRNA expression and cleavage of Casp-1 were con-
sistently reduced in both models of ethanol adminis-
tration following administration of all three tested BA 
receptor agonists. This phenotype was driven, more 
clearly in the case of INT-767, through an increase in 
PKA activity and subsequent NLRP3 ubiquitination, 
suggesting that bile acid receptor agonists play a role in 
repression of inflammasome signaling, a key driver of 
inflammation in ALD.(33) This finding is further sup-
ported by a recent report showing that bile acids nega-
tively regulate the NLRP3 inflammasome.(32)
In conclusion, our findings demonstrate that FXR/
TGR5 activation ameliorates murine ALD, providing 
the first evidence for the therapeutic potential of both 
FRX and TGR5 agonists to treat ALD. Although the 
models tested primarily represent early alcoholic ste-
atohepatitis and do not fully replicate the complex-
ity of human drinking patterns, our results provide a 
sound rationale for the clinical translation of bile acid 
receptor activation in ALD patients, and suggest that 
a combined treatment with both FXR and TGR5 ago-
nists may be most effective. Given the limited efficacy 
of current standard-of-care with steroids in alcoholic 
hepatitis, there is a significant need for new effective 
and well-tolerated therapies to increase survival and 
quality of life in patients with alcoholic hepatitis. Thus, 
FXR and TGR5 agonists deserve further investigations 
in human clinical trials in alcoholic hepatitis.
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